The FDA has approved omadacycline (Nuzyra – Paratek), a semisynthetic tetracycline derivative, for once-daily IV and oral treatment of community-acquired bacterial pneumonia (CAP) and acute bacterial skin and skin structure infections (ABSSSIs) in adults (Table 1).
Omadacycline has a broad spectrum of activity that includes gram-positive, gram-negative, atypical, and anaerobic pathogens (see CAP and ABSSSIs sections for specific clinical activity). It has been shown to have in vitro activity against some drug-resistant pathogens including penicillin-resistant Streptococcus pneumoniae, vancomycin-resistant enterococci (VRE), beta-lactamase-positive Haemophilus influenzae, Acinetobacter species, and non-ceftazidime-susceptible and non-imipenem-susceptible Enterobacteriaceae, but it is not active against Pseudomonas, Proteus, Morganella, or Providencia species.1-3
Omadacycline (Nuzyra) — A New Tetracycline Antibiotic. JAMA. 2019;322(5):457–458. doi:10.1001/jama.2019.8199
Browse and subscribe to JAMA Network podcasts!
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: